Veru announces fda grant of fast track designation for sabizabulin for the treatment of hospitalized covid-19 patients at high risk for acute respiratory distress syndrome

-- phase 3 sabizabulin covid-19 clinical study for treatment of hospitalized moderate to severe covid-19 patients at high risk for acute respiratory distress syndrome being conducted in us, mexico, south america, and europe; clinical results expected 1h 2022 -- -- second veru drug under development to receive fda fast track designation this month --
VERU Ratings Summary
VERU Quant Ranking